i am all in Spex

pps is to low, at this level it will be a huge bounce

hi!
was that a buy or a sell?

ASTM - Chart

20.01.2011 - The Sixth International Conference on Cell Therapy for Cardiovascular Disease

Presentation Title: The IMPACT-DCM Trial; 6 Month Results of Surgical Administration of CRCs

http://www.aastrom.com/eventdetail.cfm?eventid=91103

ASTM looking for a second Run!

days to cover?

anyone know the short interest?

you think it will go over 1$ with this news and the covering?
Volume is monster!

They have shortet Xoma very big!

If big buyers come -> Short Squezze

Shorts tried to make sure it is not getting a buy signal, because they have to cover ;))

XOMA Volume coming in!

i think so!

XOMA green close!

huge Buyer on XOMA right now!

XOMA next Resistance 6.90, if its broken it will fly over 7 1/2

you are trying to push and make your own profit!

.....

nznznz

yes, me!

waiting for the big Pop!

there are many naked shorts there

XOMA the Bulls are back!

in at XOMA

DARA

The Trend is your Friend :)

DARA loading up for next step!

see u at 4.47

Dara

Dara next resistance 3.92

and then


4.47

Dara next resistance 3.92

and then


4.47

any news on dara?

why is Dara going up?

Price Target is 15$

Next week leg up to 8++

strong close on Friday and Daytrader Profittaking!

Thank you for the fast warning!

and down it goes...

http://www.streetinsider.com/Corporate+News/Radient+Pharma+(RPC)+Notified+of+Notes+Offerings+Review+by+AMEX/6181357.html

whats with the bad news?
no sell off?

1.07 im IN!

Rodman & Renshaw Starts Polymedix (PYMX) at Market Outperform, Sets $3 Price Target

http://www.streetinsider.com/New+Coverage/Rodman+%26+Renshaw+Starts+Polymedix+%28PYMX%29+at+Market+Outperform,+Sets+$3+Price+Target/6179030.html

whats your price target on DEPO ?

over 7$ befor fda desicion?

40 break in AH

nice and healthy run!


RPC

RPC Downtrend is broken! nice chart!

very good news on rpc... but stock is not moving... high volume..

what is going on with rpc?

Annual Meeting

The 2010 Annual Meeting of Shareholders will be held at 10 am PST on Friday, December 3, 2010 at the Company's corporate office located at 2492 Walnut Ave, Suite 100 in Tustin, California.

RPC Radient Pharmaceuticals

BALTIMORE, Aug 26, 2010 (GlobeNewswire via COMTEX) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has published a research update on Radient Pharmaceuticals Corporation /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 0.44, -0.02, -4.26%) , a leading in-vitro diagnostics test kits provider, with a focus on the oncology/cancer segment.

Radient has won FDA approval for its lead product as a post-surgery colorectal cancer monitoring test and is the only approved product in key markets abroad as a general cancer screen. As part of its diagnostics focus, Radient is in the midst of monetizing non-core assets and business lines through divestitures and out-licensing.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.

"Radient is well-positioned to lead the global charge in a $1 billion market for a general cancer screen test kit, which could potentially save lives and substantial sums of money otherwise used for treatment. We view Radient as a stock that offers great value and potential for its existing operations, hidden but soon-to-be monetized value in its non-core assets, and home run potential with its cancer screen platform. A steady stream of news and events in the coming months should serve as catalysts for the stock," Goldman commented.

RPC will be runing in a few days when goldman sachs brings out e new article...

Price Target is 4$

fundamentaly nothing has changed!

buy the dip!

(Radient Pharmaceuticals Corporation Public, AMEX:RPC)